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1. Introduction 
Extrapulmonary neuroendocrine carcinoma (EP-NEC) have been found in most organs, but 
the most common sites are the gastrointestinal tract, cervix uteri and urogenital tract 
(Strosberg et al., 2010, Walenkamp et al., 2009). Recently it has been defined as a 
pathological entity in breast cancer (Tavassoli et al., 2003). Additionally, in up to 30% of EP-
NEC cases, no primary site can be identified (Kloppel et al., 1996). In the prior 2000 WHO 
classification, these tumours were known as poorly differentiated endocrine carcinoma 
(PDEC) (Solcia et al., 2000). In the 2010 WHO GI classification PDEC the nomenclature has 
been altered, and these tumours are now called neuroendocrine carcinoma (NEC) (Bosman 
et al., 2010). NEC tumours have a much higher proliferation rate than well-differentiated 
endocrine tumours. The terms poorly differentiated high-grade and neuroendocrine 
carcinoma are used synonymously and encompass mainly two histological entities: small-
cell neuroendocrine carcinoma (SCNEC) and large-cell neuroendocrine carcinoma (LCNEC) 
(Bosman et al., 2010). LCNEC is morphologically distinguished from SCNEC by cytological 
features of a non–small cell carcinoma, including large cell size, low nuclear to cytoplasm 
volume ratio, coarse chromatin, and frequent nucleoli. They are both characterised by 
markers of neuroendocrine differentiation with synaptophysin, neuron-specific enolase, 
chromogranin and CD56 being the primary stains.  They are also characterised by a high 
mitotic rate (defined as >10 mitotic figures per 10 high-power fields or a ki-67 > 20% in the 
gastrointestinal (GI) tract and other extrapulmonary sites and often with extensive necrosis. 
Most carcinomas in this family exhibit substantially more mitoses than these thresholds, 
typically in the range of 40 to 70 mitoses per high-power fields. Up to 40% of NECs contain 
elements of non-NECs, usually adenocarcinoma or squamous cell carcinoma. Often the 
diagnosis of a NEC tumor is after surgery on examination of the histological specimen. 
NECs are characterised by a high proclivity for metastatic dissemination even in patients 
with clinically localised tumours. This principle is validated by retrospective studies 
confirming that surgery alone is rarely curative (Brenner et al.,2004a). 
In devising treatment strategies for extrapulmonary NEC, many authors refer to the 
extensive literature surrounding high-grade neuroendocrine carcinoma of the lung (Brenner 
et al., 2004a, Walenkamp et al., 2009). Several series have, however, questioned the rationale 
for this, and point out many differences between pulmonary small-cell carcinoma and 
SCNEC  (Brennan et al., 2010, Brenner et al., 2004a, Brenner at al., 2007, Ku et al., 2008). 
Differences include aetiology (less smoking history in SCNEC), frequency of brain 
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metastases (less in SCNEC), overall survival (superior in SCNEC, and survival may be site 
specific, i.e. gynaecologic and head and neck cancers may have better outcomes than GI 
primaries), and molecular differences, e.g. BCl-2 overexpression is more common in lung 
compared with SCNEC. Guidelines for treating EP- NEC advocate the use of combination 
chemotherapy with a platinum-based chemotherapy combined with the etoposide (NCCN 
2010). No other regimen has consistently shown a benefit over this combination. When a 
patient has disease limited to the lung, using an aggressive multi-modality therapy 
including platinum-based chemotherapy and thoracic radiotherapy has showed improved 
survival. Based on this treatment paradigm for limited-stage small-cell lung cancer, a course 
of definitive chemotherapy and local therapy (surgery or radiation) can be considered in 
many patients with loco-regional EP- NEC. Whereas there are no studies examining 
adjuvant chemotherapy in NEC, their aggressive behaviour warrants consideration of 
adjuvant therapy in most cases. The North American Neuroendocrine Tumor Society 
(NANETS) recommend 4-6 cycles of cisplatin or carboplatin and etoposide as adjuvant 
therapy for resected patients (Strosberg et al., 2010). The use of neoadjuvant chemotherapy 
has by many been advocated for these patients, as surgery or radiation often has a poor 
prognosis due to the frequent development of distant metastases. Recently, neoadjuvant 
chemotherapy for resectable gastric cancer and resectable liver metastasis from colorectal 
cancer has been shown to increase survival (Cunningham et al., 2006, Nordlinger et al., 
2008). Potential advantages to a neoadjuvant approach include; earlier treatment of 
micrometastatic disease; better compliance to treatment; determination of responsiveness to 
chemotherapy which can be prognostic and help in planning of postoperative 
chemotherapy;  and avoidance of unnecessary surgery for patients with early systemic 
disease progression. Potential disadvantages include the risk of missing the window of 
opportunity for resection because of disease progression. The present paper discuss 
available literature concerning the use of neoadjuvant chemotherapy for EP-NEC. 
2. Gastrointestinal neuroendocrine carcinoma 
2.1 Background 
Extra-pulmonary neuroendocrine carcinomas can originate anywhere in the gastrointestinal 
(GI) tract, but are mainly located in the oesophagus, stomach, pancreas and colon (Brenner 
et al., 2004a). Few data exist about this tumor group as many have been included in the 
general neuroendocrine tumor group and many are frequently misdiagnosed as poorly 
differentiated adenocarcinoma. GI primary tumours account for 35-55% of all NEC outside 
the lung (Galanis et al., 1997, Lee et al., 2007). Approximately 10% of all GI neuroendocrine 
tumours are NEC. Most GI NEC's are metastatic at the time of diagnosis. In the SEER 
database, colorectal NEC has an incidence of 2/1,000,000 inhabitants/year, and distant 
disease at diagnosis was present in 62% of patients (Kang et al., 2007). Median survival from 
diagnosis in untreated patients is usually 4-6 months, indicating a very rapidly growing 
tumor. Among 94 GI NEC patients in the National Cancer registry of Spain, 67% presented 
as distant metastatic disease, median survival was 1.7 months and 39% alive at 5 year 
(Garcia-Carbonero et al., 2010). Morphologically GI NEC are classified in two types: a small-
cell carcinoma, resembling small-cell carcinoma of the lung, and a large-cell pleomorphic 
carcinoma (Bosman et al., 2010) (Figure 1-2). Small-cell histological preponderance in the 
squamous GI tract (oesophagus and anus) and large-cell carcinomas in the glandular parts 
(Shia et al., 2008). Awareness of the latter is essential, as these tumours often are 
indistinguishable from poorly differentiated non-NET carcinomas.  
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Fig. 1. Small-cell NEC from pancreas. 
 
 
Fig. 2. Large-cell NEC from colon. 
Usually synaptophysin will be positive in immunohistochemistry while staining for 
chromogranin A (CgA) is present at a lower level (Figure 3-4). The presence of CgA 
indicates a more mature tumor, and the presence of both markers is a good prognostic sign 
(Faggiano A et al., 2007, Welin et al., 2011). Several pathologists advocate for routine 
staining with synaptophysin and chromogranin for all tumours initially classified as poorly 
differentiated gastrointestinal adenocarcinoma.  
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Fig. 3. Synaptophysin positive NEC. 
 
 
Fig. 4. Chromogranin A positive NEC. 
CD56 is another neuroendocrine marker, which can help to classify a tumour. Screening for 
CgA in serum should be done, but is usually negative and hormonal symptoms are rare 
(Janson et al., 2010). In most NET guidelines it is stated that somatostatin receptor 
scintigraphy is usually negative in NEC. A somatostatin receptor scintigraphy should 
however be performed if ki-67 is below 30-40%, when peptide receptor radionucleotide 
therapy (PRRT) is a future treatment option. Ki-67 is per definition >20% but is more likely 
to be between 50 and 100% (Figure 5-6).  
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Fig. 5. SCNEC with a ki-67 index of 50%.  
 
 
Fig. 6. LCNEC with a ki-67 index of 80-90% 
In many patients, metastatic disease is present at time of diagnosis. In some instances the 
primary can be found, but often the primary will be of uncertain origin but usually 
considered GI if the metastatic load is dominating in liver and abdomen. Despite rare 
reports of long-term survivors, surgery alone is inadequate therapy even for apparently 
localised disease. Many operated patients have a rapid recurrence after surgery. Adjuvant 
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radiotherapy for incompletely resected disease and systemic chemotherapy are widely 
recommended, although the effectiveness of a combined modality approach has not been 
firmly established. Despite aggressive multi-modality therapy including surgery and 
systemic chemotherapy, the median survival in colorectal SCC was six months, with only 
15% of patients alive at one-year (Hung 1989). Data from Memorial Sloan Kettering Cancer 
Centre show a median survival of ten months for patients with colorectal SCC (Bernick et 
al., 2004). One-year, two-year, and three-year survival was 46%, 26%, and 13%, respectively. 
There are no significant differences in survival based on pathologic subtypes (Bernick et al., 
2004, Shia et al., 2008). In a series of 53 cases of gallbladder SCC, those with disseminated 
disease had a median survival of eight months after treatment with combination 
chemotherapy. One and two year survival rates were 28% and 0%, respectively (Fujii et al. 
2001). In the SEER database of colorectal NEC, 5-year survival was 21% for all stages, 
ranging from 73% in localised disease to 6 % in distant disease (Kang et al., 2007). 
2.2 Neoadjuvant chemotherapy  
Extensive disease (ED) is almost invariably treated by systemic chemotherapy. In contrast, 
the treatment approach for limited disease (LD), a potentially curable condition, is presently 
neither consistent nor uniform. While some authors used only local therapies, mostly 
surgery and occasionally radiotherapy, others advocate the use of chemotherapy, even 
alone, in these patients. NEC do not respond to treatments usually applied in other 
neuroendocrine tumours such as somatostatin analogues and interferon (Alhmann et al., 
2008, Nilson et al. 2006). For patients with disease localised within an anatomic region 
(limited disease), initial neoadjuvant therapy with chemotherapy or chemoradiotherapy is 
an option, followed by surgery if no distant metastases are identified and the locoregional 
disease is resectable. Usually 2-3 cycles are given before surgery (Figure 7).  
 
 
   
 
Fig. 7. Partial response after 4 cycles of neoadjuvant cisplatin/etoposide before radical 
surgery in a patient with unknown primary NEC. 
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No convincing data exist concerning adjuvant postoperative chemotherapy, but most 
recommend postoperative chemotherapy with the same drugs for 3-4 months as part of 
the neoadjuvant approach. Adjuvant or neoadjuvant chemotherapy is based on the effect 
in a metastatic setting, and is usually given with cisplatin /carboplatin and etoposide 
with response rates between 41- 67% (Mitry et al., 1999, Moertel et al., 1991). Casas and 
colleagues highlighted the role of systemic chemotherapy and local treatment in small-cell 
carcinomas of the oesophagus. In a retrospective series of 199 patients, improved median 
survival from 5 to 20 months was reported in patients with localised disease who received 
multi-modal therapy, i.e. surgery, radiation therapy, and systemic treatment (Casas et al., 
1997). A prognostic factor analysis found that local therapy only (e.g. surgery alone) was 
the single most powerful predictor of poor prognosis. In the prognostic factor analysis, 
chemotherapy was found to be strongly associated with improved survival, both in LD 
and ED.  Recent data from Memorial Sloan Kettering Cancer Centre support the use of 
induction chemotherapy followed by consolidative chemoradiation for patients with 
limited disease oesophageal SCNEC (Ku et al., 2008). Median survival was 20 months in 
this single institute retrospective study of 25 oesophageal SCNEC patients, with two 
limited disease patients alive and free of disease after five years follow-up. The authors 
concluded that surgery might not be necessary as part of initial therapy if a clinical 
complete response is achieved after chemoradiation, and that surgery may be reserved for 
salvage after documented local failure. In 64 patients with GI NEC seen at Memorial Sloan 
Kettering Cancer Center between 1980 and 2002,the most common primary tumour 
locations were in the large bowel and oesophagus (Brenner et al., 2004b). Sixteen patients 
with LD received chemotherapy, 12 of whom received it in conjunction with either 
surgery or radiotherapy. Of these, two remained alive with no evidence of disease for at 
least 64 and 94 months and one expired with no evidence of recurrence after almost 9 
years. The authors suggests a potential role for surgery for LD; half of the operated 
patients retained locoregional control, and four of the six long-term survivors had 
surgery; two of them with no other treatment. The authors also state that this study 
supports the effectiveness of chemotherapy on survival in this disease; three of the long-
term survivors received chemotherapy and six patients were treated by a combination of 
surgery and chemotherapy. Two of these had no evidence of disease for over 7 years and 
locoregional control was preserved in three. At present, in the absence of data derived 
from prospective clinical trials, they recommend to treat patients with LD with pre- or 
postoperative chemotherapy.  
In contrast to metastatic neuroendocrine tumours with a low ki-67, debulking surgery and 
surgery for liver metastasis is generally not recommended in NEC patients due to the high ki-
67 level. In some patients, however, this may still be an option. In one of our patients, surgery 
for extensive metastatic disease after neoadjuvant chemotherapy resulted in long time survival 
(Figure 8) (Sorbye et al., 2007). Similar case reports of neoadjuvant chemotherapy before 
locoregional treatment of metastatic NEC lesions have been reported (Power et al., 2010). 
Altogether, most data support that in patients presenting with limited disease NEC of the 
gastrointestinal tract, a combination of systemic platinum-based chemotherapy combined 
with local treatment consisting of radiotherapy, surgery or both offer the best chance for 
long-term survival. Based on the high rate of micrometastatic disease presentation, several 
authors suggest that a sequence of neoadjuvant chemotherapy followed by definitive 
surgery seems appropriate, although the reverse sequence of surgery followed by adjuvant 
chemotherapy can not be excluded (Brenner et al., 2007).  
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Fig. 8. Partial response of liver metastases and lymph node metastases after 4 cycles of 
neoadjuvant chemotherapy with cisplatin/etoposide before radical surgery and long-term 
survival. 
3. Neuroendocrine cancer of the uterine cervix 
3.1 Background 
Neuroendocrine tumours of the uterine cervix represent 1–2% of cervical cancers and are the 
2nd most common extra-pulmonary location of the primary tumor for NEC (Crowder et al., 
2007). They are classified as typical carcinoid tumours, atypical carcinoid tumours, small-cell 
neuroendocrine carcinomas (SCNEC) and large-cell neuroendocrine carcinomas (Figure 9). 
Small-cell neuroendocrine carcinoma is the most common, and is aggressive with a high 
chance of distant metastasis and poor prognosis, even with combinations of treatments. 
The natural history of this disease differs from the more commonly seen squamous cell or 
adenocarcinoma of the cervix. Patients diagnosed with SCNEC are more likely to have 
lymph node metastases and lymphovascular space invasion, and their clinical course is 
frequently marked by local and distant failure. Five-year survival rates vary from 31-36% for 
early disease and 0-14% for advanced disease (Chen et al., 2008). Long-term survival can be 
achieved only in patients with limited stage disease. Limited stage disease, which is defined 
as disease that can be encompassed within a radiation field, is treated with curative intent 
with combined modality therapy, with approximately 30% of patients achieving a cure 
(Figure 10). Patients with extensive stage disease – defined as disease outside of these 
confines – have a dismal prognosis with few surviving beyond two years. Clear treatment 
recommendations for SCNEC have not been defined. Due to the rarity of this disease it has 
been difficult to conduct prospective trials. Based on retrospective studies and treatment 
paradigms established for small-cell lung carcinoma, many clinicians favour the use of 
combined modality therapy for limited stage disease, definitive chemoradiation therapy for 
locoregional advanced disease and palliative chemotherapy for metastatic disease. It is not 
known if these treatment modalities ultimately improve survival. Often, the diagnosis of 
small-cell is not made until receipt of the final pathology on a radical hysterectomy; once the 
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diagnosis is made, prompt initiation of combined modality therapy should follow post-
operatively. The role of surgery for SCNEC is not well studied. It is unclear which patients, 
if any should undergo radical hysterectomy as opposed to primary combined chemotherapy 
and radiation therapy. If small cell histology is known, it is probably most appropriate to 
proceed with chemotherapy followed by surgery and postoperative chemotherapy or 
postoperative chemoradiation.  
 
 
 
 
   
Fig. 9. Small-cell neuroendocrine cancer of uterine cervix, ki-67 about 60% 
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Fig. 10. PET/CT and MRI of a localised uterine cervix NEC before initiation of neoadjuvant 
chemotherapy.  
3.2 Neoadjuvant chemotherapy 
In a retrospective review of 188 patients of small-cell carcinoma of the uterine cervix, 135 
patients had stages I-IIA, 45 stages IIB-IVA, and 8 stage IVB disease (Cohen et al., 2010). 
Adjuvant chemotherapy or chemoradiation was associated with improved survival in 
patients with stages IIB-IVA disease compared with those who did not receive 
chemotherapy (17.8% vs 6.0%; P = .04). On multivariable analysis, early-stage disease and 
use of chemotherapy or chemoradiation were independent prognostic factors for 
improved survival. Hoskins et al. reported 31 patients who were treated with protocols 
using etoposide, cisplatin and radiation therapy with concurrent chemotherapy with or 
without the addition of carboplatin and paclitaxel (Hoskins et al., 2003). The 3-year 
failure-free rate of the patients with early stage disease (stage I and II) was 80%. Chang et 
al. analysed 40 cases of small-cell uterine cervical carcinoma treated with primary 
hysterectomy followed by adjuvant chemotherapy containing a combination of 
vincristine, doxorubicin and cyclophosphamide or cisplatin and etoposide (Chang et al., 
1998). Median survival was 47 months, signifying the importance of adjuvant 
chemotherapy for early stage small-cell cervical carcinoma after radical hysterectomy.  A 
recent study from Korea retrospectively reviewed 68 patients (Lee et al., 2008). Seven were 
treated with radical surgery alone; 11 with neoadjuvant chemotherapy followed by 
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radical surgery; 24 with radical surgery followed by adjuvant chemotherapy; and 26 with 
radical surgery followed by adjuvant radiation or chemoradiation. After a median follow-
up of 44 months, the two-year and five-year survival for all patients was 65% and 47%, 
respectively. Patients who received neoadjuvant chemotherapy had a worse prognosis 
than those who did not receive neoadjuvant chemotherapy, but the patients who received 
neoadjuvant therapy had worse baseline prognostic factors. Adjuvant chemoradiation did 
not improve survival compared with adjuvant chemotherapy alone. In a study with 17 
patients with SCNEC in uterine cervix, all 5 patients with early stage disease without 
chemotherapy as part of their initial treatment developed distant metastases within 2 
years from the diagnosis (Zivanovic et al., 2009). This was in contrast to the 6 patients 
who were treated with adjuvant platinum- and etoposide-based combination therapy. In 
this group, only 1 patient developed systemic disease. In a retrospective analyses of 62 
patients with large-cell NEC of the uterine cervix, median age was 37 and FIGO stage was: 
58% stage I, 16% stage II, 2% stage III and 8% stage IV disease (Embry et al., 2011). Median 
overall survival for stage I, II, III, and IV cancers was 19, 17, 3, and 1.5 months, 
respectively. Thirty-seven women (60%) received chemotherapy as part of their initial 
treatment plan. In a multivariate analysis, earlier stage and the addition of chemotherapy 
were associated with improved survival. Both platinum agents and platinum and 
etoposide together were associated with improved survival.  
Among 20 patients with neuroendocrine cervical carcinoma, patients with stage Ib2 or 
greater received neoadjuvant chemotherapy with vincristine, bleomycin, and platinum 
(Bermudez et al., 2001). The response was <50% in 2/13 cases (15%), >50% in 9/13 (69%), 
and complete in 2/13 (15%), and resection was successfully performed in all 13 patients.  
Patients with initial tumor volume less than 4 cm had no recurrences and 5-year survival 
was 76%, whereas 75% recurred and 5-year survival was only 18% when initial tumor 
volume was over 4 cm (Figure 11). 
 
 
   
 
Fig. 11. Complete response of small-cell NEC of uterine cervix after 2 cycles of neoadjuvant 
chemotherapy with cisplatin and etoposide preceding planned surgery. 
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Although the comparison between different series is problematic due to selection bias and 
different treatment strategies, data support that in patients with early stage disease NEC of 
the uterine cervix, the addition of systemic platinum-based chemotherapy appears to have a 
protective effect on the development of distant metastases. The association between 
chemotherapy and local therapy (surgery/radiation) seems to obtain the best results in 
terms of survival. However, the sequence at which both therapeutic modalities should be 
used has not been proven yet. 
4. Neuroendocrine carcinoma of the bladder 
4.1 Background 
In the urinary system, the majority of cases have been observed in the bladder and prostate. 
Small-cell neuroendocrine carcinoma accounts for less than 1% of all bladder tumours, 
whereas large-cell neuroendocrine carcinoma is even rarer. Like small-cell carcinoma of the 
lung, small-cell carcinoma of the bladder has a propensity for early metastases. Only about 
one third (14–44%) of the patients present with limited disease. Given the lack of evidence to 
the contrary, a radical cystectomy has been considered the “de facto” standard for patients 
without evidence of metastatic disease. However, the lack of efficacy of this approach is 
readily apparent; even in recently published series, most patients die within 2 years of 
cystectomy (Cheng et al., 2004, Quek et al., 2005). Management ranges from cystectomy 
alone, with or without adjuvant radiation therapy or adjuvant chemotherapy. Recent 
retrospective reviews suggest better survival with initial chemotherapy followed by local 
consolidation with cystectomy or radiation (Church & Bahl 2006). The use of preoperative 
chemotherapy follows from the frequent observation of rapid growth rates and typical 
upstaging on initial surgery, not uncommonly leading to aborted cystectomy. The benefits 
of incorporating neoadjuvant chemotherapy can be multifold. Whereas it may take time to 
schedule an operation or for patients in this age group to complete preoperative clearance, 
systemic chemotherapy can be initiated quickly, providing timely control of this rapidly 
growing chemotherapy-sensitive tumor. Tumor can frequently be downstaged, resulting in 
a surgery that is more likely to achieve negative margins and the pathologic stage after 
preoperative chemotherapy may provide valuable prognostic information. 
4.2 Neoadjuvant chemotherapy 
In a retrospective review of 25 patients with neuroendocrine tumor of the bladder, Quek 
and associates reported significant improvement in recurrence-free and overall survival 
(OS) in those receiving neoadjuvant or adjuvant chemotherapy with radical cystectomy as 
compared with radical cystectomy alone (Quek et al., 2005). Walther et al observed that five 
of seven patients were alive and cancer free at 36 months, most as a result of preoperative 
chemotherapy (Walther et al., 2002). A study from M.D. Anderson Cancer Centre reported 
similar results with regard to neoadjuvant chemotherapy but not with adjuvant 
chemotherapy (Siefker-Radtke et al., 2004). Of the 88 patients 46 underwent cystectomy, 
including 25 who were treated with initial cystectomy and 21 who received preoperative 
chemotherapy. For patients treated with initial cystectomy median cancer specific survival 
(CSS) was 23 months, with 36% disease-free at 5 years. For patients receiving preoperative 
chemotherapy median CSS had not been reached, although CSS at 5-years was 78% with no 
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cancer related deaths observed beyond 2 years. Notably 7 of 25 patients treated with initial 
cystectomy received chemotherapy after surgery, but their survival was no better than those 
treated with cystectomy alone. As others have observed, the pathological stage was higher 
than clinically appreciated for 56% of patients treated with initial cystectomy. There were no 
cancer related deaths among patients with disease that was downstaged to pT2 or less. 
Other studies, however, have shown no survival benefit between cystectomy and multi-
modal therapy. Cheng et al. reported no survival benefit in 64 cases of SCC in those 
undergoing cystectomy alone compared with multi-modal treatment (Cheng et al., 2004). 
Still, a one-year disease specific survival difference of 66% versus 45% was observed among 
patients who received combination therapy, compared to those who underwent cystectomy 
only. A retrospective report from the Mayo Clinic advocates surgery alone in patients with 
surgically resectable tumours, especially for those with muscle-invasive tumours 
(pT2N0M0) (Choong et al., 2005). Although it is not clear how many patients were upstaged 
at surgery, of 12 patients with pT2N0M0 small-cell urothelial cancer, the 3-year OS rate was 
63.6%. However, half of these patients experienced relapse. The Mayo Clinic results are also 
in marked contrast to another retrospective study that suggests an approximately 25% 3-
year survival rate in 30 patients with organ-confined disease (≤ pT2N0M0). In a study of 106 
cases of SCC bladder cancer, only cisplatin chemotherapy predicted survival on multivariate 
analysis (Mackay et al., 1998). Initial stage was not independently associated with survival, 
which strongly suggests that micrometastatic disease is usually present at presentation in 
clinically localised tumours and systemic metastases are the major cause of mortality. In the 
most recent study, 4 cycles of neoadjuvant chemotherapy were given to small-cell urothelial 
cancer in a phase II trial  (Sifker-Radtke 2009). 18 patients with surgical resectable cancer 
received neoadjuvant treatment with a median survival of 58 months, 13 are still cancer free 
and alive. Pathologic downstaging was quite frequent, with an improved survival in those 
downstaged to ≤ pT2N0M0. The largest impact on survival seemed to be in patients with 
muscle-invasive bladder cancer.  
In the absence of a large comparative trial, definitive conclusions cannot be drawn regarding 
the best multi-modality strategy for the treatment of neuroendocrine carcinoma of the 
bladder. Currently available literature suggests that local therapy with surgery or 
radiotherapy alone is not optimal, and that integrating chemotherapy can improve long-
term disease control. Recent results suggest that neoadjuvant chemotherapy followed by 
localised therapy to the pelvis may be the optimal strategy. Whether radiation or cystectomy 
provides optimal local consolidation is not currently known.  
5. Neuroendocrine carcinoma of the prostate 
5.1 Background 
Prostate cancer is one of the most common types of extra-pulmonary small-cell carcinoma, 
accounting for 10% of all EP-NEC (Asmis et al., 2006). Pure SCC is rare at initial 
presentation, accounting for less than two percent of all prostate malignancies. Small cell 
carcinoma prostatic disease has a worse prognosis than SCC bladder disease (Mackey et al., 
1998). Three patterns of small-cell carcinoma are known: one third present as pure small-cell 
carcinoma; one fifth of cases present with combined adenocarcinoma; and approximately 
half present as recurrence of small-cell carcinoma from conventional adenocarcinoma. Many 
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prostatic adenocarcinomas show areas of focal neuroendocrine differentiation, and many 
extrapulmonary small-cell carcinomas of the prostate are associated with an 
adenocarcinoma component. In patients with mixed prostate cancer that has metastasised, it 
is often unclear whether the metastatic disease is of the adenocarcinoma component, the 
SCC component or both since biopsies of metastatic lesions are typically not done. Because 
this type of prostate cancer essentially has two tumor types, it may be beneficial to biopsy 
any atypical metastatic lesion. Clinically, prostate cancer with SCC component act 
differently from pure adenocarcinoma. Typical features of a mixed tumor type include; 
elevated neuroendocrine markers such as serum chromogranin A, low to normal PSA, early 
disease progression, resistance to androgen deprivation and high-grade disease. Small-cell 
carcinomas of the prostate do not express androgen receptors. These features warrant 
aggressive multi-modal therapy. Small-cell neuroendocrine carcinoma of the prostate is a 
highly aggressive tumor, presenting early metastasis to soft tissues and bone without a 
commensurate with serum PSA level.  
5.2 Neoadjuvant chemotherapy 
For patients with mixed adenocarcinoma/SCC prostate cancer, the standard treatment 
regimen includes hormonal therapy in combination with systemic etoposide/cisplatin 
chemotherapy. Whether chemotherapy is effective for long term survival for patients with 
small cell prostate carcinoma is controversial. Vinblastine, doxorubicin, and 
cyclophosphamide, or platinum (cisplatin or carboplatin) compound-based regimens 
combined with etoposide, or etoposide and doxorubicin, are recommended for the initial 
treatment. Therapy usually results in a 60% response rate, median survival is approximately 
one-year whereas long-term survival is rare (Amato et al., 1992, Palmgren et al., 2007). 
Immediate chemotherapy with or without hormonal therapy for both pure SCC and mixed 
adenocarcinoma of the prostate resulted in longer clinical remissions in retrospective study, 
although none survived (Moore et al., 1992). In a single centre study performed at M.D. 
Anderson Cancer Centre with 83 patients, 26 had no evidence of metastatic disease at the 
time of diagnosis (Spiess et al., 2007). The most common form of initial therapy for SCC of 
the prostate was systemic chemotherapy containing etoposide and/or a platinum 
compound, given either alone (38 patients), combined with androgen deprivation therapy 
(ADT) (29 patients), with radiotherapy and ADT (6 patients) or with surgery and ADT (3 
patients). The use of systemic chemotherapy was not found to be a predictor of PFS and 
disease-free survival in this study, because the majority of patients (92%) received it as 
initial therapy. In a retrospective study of 60 SCC prostate cancer patients, primary surgical 
therapy was the only parameter that predicted survival on univariate analysis (Mackey et 
al., 1998). In contrast to bladder SCC, no benefit of chemotherapy was found for prostate 
primary tumours. Within the framework of the Rare Cancer Network Study, 30 patients 
suffering from small-cell neuroendocrine prostate cancer were examined, either in an 
early/localised or an advanced/metastatic stage (Stein et al., 2008). Patients were treated 
with cisplatin-based chemotherapy, with or without pelvic radiotherapy. Two patients with 
early disease achieved complete remission for a duration of 19 and 22 months. Twenty-five 
patients succumbed to massive local and/or distant failure. Despite initial response, the 
common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome 
markedly.  
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In conclusion, for localised non-metastatic small-cell neuroendocrine prostate, initial 
therapy with platinum-based chemotherapy is usually recommended, but the long term 
benefit is uncertain. 
6. Neuroendocrine carcinoma of the breast 
6.1 Background 
Neuroendocrine carcinoma of the breast is one of the least common types of breast cancer 
with data consisting of only case reports in the literature. All the tumours described showed 
morphological and immunohistochemical similarities to the breast metastases of pulmonary 
small cell carcinoma, the most distinguishing feature are the absence of primary small-cell 
cancer elsewhere. In 2003, the World Health Organization (WHO) recommended 
classification of these tumours into three histologic types: solid, small-cell, and large-cell 
neuroendocrine carcinoma (Tavassoli et al., 2003). Seventy-four patients with NEC of the 
breast who were treated at M. D. Anderson Cancer Center were recently analysed. NEC 
showed a more aggressive course than invasive ductal carcinoma, with a higher propensity 
for local and distant recurrence and poorer overall survival (Wei et al., 2010). No standard 
treatment protocol has been defined with certainty due to the small number of cases. 
Modified radical mastectomy with axillary lymph node dissection seems to be the treatment 
of choice, with adjuvant radiation, chemotherapy or both, based on the clinical stage and 
presence of metastasis. Data suggest using different chemotherapy schedules than ordinary 
used in breast cancer treatment. Most studies show that the SCNEC of breast is a very 
aggressive neoplasm and has in general a worse prognosis than the usual ductal types, but 
may have a good prognosis depending on the initial stage of the disease (Wei et al., 2010). 
6.2 Neoadjuvant chemotherapy 
There are case reports on the use of neoadjuvant chemotherapy for SCC of the breast and 
one patient with a complete response after cisplatin and etoposide treatment (Mirza & 
Shahab, 2007). Treatment and outcome information for 60 patients with NEC of the breast at 
M. D. Anderson Cancer Center show that among 14 patients who received cisplatin-based 
neoadjuvant chemotherapy only 1 patient had recurrence of disease (Wei et al., 2010). 
Among the other 46 patients where 38 received postoperative chemotherapy, 18 patients 
had a recurrence of disease indicating that neoadjuvant chemotherapy might be superior to 
postoperative treatment. 
7. Conclusion 
In the absence of large comparative trials, definitive conclusions cannot be drawn regarding 
the best multi-modality strategy for the treatment of EP-NEC. Currently available literature 
suggests that local therapy with surgery or radiotherapy alone is not optimal and that 
integrating platinum-based chemotherapy can improve long-term disease control and 
survival. Most data support that patients presenting with limited disease EP-NEC of the GI, 
bladder, breast and uterine cervix should be treated with systemic platinum based 
chemotherapy combined with local treatment consisting of radiotherapy, surgery or both. 
The sequence at which both therapeutic modalities should be used has not been proven yet, 
but recent results for NEC in bladder and breast indicate that neoadjuvant chemotherapy 
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might be superior to postoperative treatment. Secondary surgery can be considered after 
neoadjuvant chemotherapy in highly selected patients with metastatic disease. 
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